


Claims:

1. A medicament for preventing and/or treating HIV infectious diseases comprising, as an active ingredient, a glucopyranose derivative of formula (J):




(wherein X represents an oxygen atom or a methylene group;

R represents a hydrogen atom, a hydroxyl group, or a C1-4 alkoxy group;


G represents:

- (1) a group of formula:



(wherein R¹ represents a single bond or a C2-20 oxycarbonylalkylene group;


R² represents hydrogen atom or a group of formula:



(in each formula, the ring A represents a C5-15 carbon ring; R⁸ represents a hydrogen atom, a C1-7 alkyl group, a C1-7 alkoxy group, or a halogen atom; and m represents 1, 2 or 3);


R³ represents a C1-20 alkylene group; and

R⁴ represents a hydrogen atom or a group of formula:



(in each formula, the ring B represents a C5-15 carbon ring; R^9 represents a hydrogen atom, a C1-7 alkyl group, a C1-7 alkoxy group, or a halogen atom; and n represents 1, 2 or 3)), or


(2) a group of formula:




(wherein Y represents a single bond or a C1-4 alkylene group; and p and q each independently represents an integer of 6 to 12);

R^5 represents a C2-20 oxycarbonylalkylene group;

R^6 represents a hydrogen atom or a group of formula:



(wherein the ring A, R^8 and m have the same meanings as described above), or a combination of R^5 - R^6 represents a group of formula:




(wherein Z represents a single bond or a C1-4 alkylene group; and r and s each independently represents an integer of 6 to 12); and

R⁷ represents a hydrogen atom, a methyl group, a hydroxymethyl group, or a sulfoxymethyl group;

with the proviso that

- (1) when R¹ represents a C2-20 oxycarbonylalkylene group, R² is bound to the alkyl group in R¹,
- (2) when R⁵ represents a C2-20 oxycarbonylalkylene group, R⁶ is bound to the alkyl group in R⁵,
or a non-toxic salt thereof;

2. A medicament for prevention and/or treatment described in claim 1, comprising as an active ingredient, a glucopyranose derivative of formula (I):




(wherein X represents an oxygen atom or a methylene group;

R represents a hydrogen atom, a hydroxyl group, or a C1-4 alkoxy group;


G represents:

- (1) a group of formula:



(wherein R¹ represents a single bond or a C2-20 oxycarbonylalkylene group;

R² represents a hydrogen atom or a group of formula:



(in each formula, the ring A represents a C5-15 carbon ring; R^8 represents hydrogen atom, a C1-7 alkyl group, a C1-7 alkoxy group, or a halogen atom; and m represents 1, 2 or 3);


R^3 represents a C1-20 alkylene group; and

R^4 represents a hydrogen atom or a group of formula:



(in each formula, the ring B represents a C5-15 carbon ring; R^9 represents a hydrogen atom, a C1-7 alkyl group, a C1-7 alkoxy group, or a halogen atom; and n represents 1, 2 or 3)), or


(2) a group of formula:




(wherein Y represents a single bond or a C1-4 alkylene group; and p and q each independently represents an integer of 6 to 12);

R^5 represents a C2-20 oxycarbonylalkylene group;

R^6 represents hydrogen atom or a group of the formula:



(wherein the ring A, R^8 and m have the same meanings as described above), or a combination of R^5 - R^6 represents a group of formula:




(wherein Z represents a single bond or a C1-4 alkylene group and r and s each independently represents an integer of 6 to 12);

R⁷ represents a hydrogen atom, a methyl group, a hydroxymethyl group, or a sulfoxymethyl group;

with the proviso that


- (1) when R¹ represents a C2-20 oxycarbonylalkylene group, R² is bound to the alkyl group in R¹,
 - (2) when R⁵ represents a C2-20 oxycarbonylalkylene group, R⁶ is bound to the alkyl group in R⁵), and
 - (3) when R⁷ represents a methyl group, a hydroxymethyl group, or a sulfoxymethyl group, R², R⁴ and R⁶ do not represent hydrogen atoms at the same time),
- or a non-toxic salt thereof as an active ingredient.

3. A medicament for prevention and / or treatment described in claim 2, comprising as active ingredient, a glucopyranose derivative of formula (I-A)




(wherein all symbols are the same meaning as defined in claim 2) or a non-toxic salt thereof.

4. A medicament for prevention and / or treatment described in claim 2, comprising as active ingredient, a cyclohexane derivative of formula (I-B)




(wherein all symbols are the same meaning as defined in claim 2) or a non-toxic salt thereof.

5. A medicament for prevention and / or treatment described in claim 2, comprising as active ingredient, 2-deoxy-2-[3S-(9-phenylnonanoyloxy)tetradecanoyl]amino-3-O-(9-phenylnonanoyl)-4-O-sulfo-D-glucopyranose of formula (I-a)



or a non-toxic salt thereof.


6. A glucopyranose derivative of formula (W):



(wherein X^w represents an oxygen atom or a methylene group;
 R^w represents a hydrogen atom, a hydroxyl group, or a C1-4 alkoxy group;

G^w represents:

(1) a group of formula:



(wherein R^{1w} represents a single bond or a C2-20 oxycarbonylalkylene group;

R^{2w} represents a hydrogen atom;

R^{3w} represents a C1-20 alkylene group;

R^{4w} represents a hydrogen atom;

R^{5w} represents a C2-20 oxycarbonylalkylene group;

R^{6w} represents a hydrogen atom; and

R^{7w} represents a methyl group, a hydroxymethyl group, or a sulfoxymethyl group;

with the proviso that

(1) when R^{1w} represents a C2-20 oxycarbonylalkylene group, R^{2w} is bound to the alkyl group in R^{1w} , and

(2) when R^{5w} represents a C2-20 oxycarbonylalkylene group, R^{6w} is bound to the alkyl group in R^{5w}),

or a non-toxic salt thereof.

7. A compound described in claim 6, which is

(1) 2-deoxy-2-[3R-(tetradecanoyloxy)tetradecanoyl]amino-3-O-tetradecanoyl-4-O-sulfo-D-glucopyranose,

(2) 2-deoxy-2-octadecanoylamino-3-O-tetradecanoyl-4-O-sulfo-D-glucopyranose,

- (3) 2-deoxy-2-[3S-(tetradecanoyloxy)tetradecanoyl]amino-3-O-tetradecanoyl-4-O-sulfo-D-glucopyranose,
- (4) 2-deoxy-2-[3R-(hexanoyloxy)tetradecanoyl]amino-3-O-hexanoyl-4-O-sulfo-D-glucopyranose,
- (5) 2-deoxy-2-[3R-(decanoyloxy)tetradecanoyl]amino-3-O-decanoyl-4-O-sulfo-D-glucopyranose,
- (6) 2-deoxy-2-[3R-(dodecanoyloxy)tetradecanoyl]amino-3-O-dodecanoyl-4-O-sulfo-D-glucopyranose,
- (7) 2-deoxy-2-[3R-(hexadecanoyloxy)tetradecanoyl]amino-3-O-hexadecanoyl-4-O-sulfo-D-glucopyranose,
- (8) 2-deoxy-2-[3R-(octadecanoyloxy)tetradecanoyl]amino-3-O-octadecanoyl-4-O-sulfo-D-glucopyranose,
- (9) 2-deoxy-2-[3R-(nonadecanoyloxy)tetradecanoyl]amino-3-O-nonadecanoyl-4-O-sulfo-D-glucopyranose,
- (10) 2-deoxy-2-tetradecanoylamino-3-O-tetradecanoyl-4-O-sulfo-D-glucopyranose,
- (11) 2-deoxy-2-[3R-(tetradecanoyloxy)tetradecanoyl]amino-3-O-tetradecanoyl-4-O-sulfo-6-O-sulfo-D-glucopyranose,
- (12) 2,6-deoxy-2-[3R-(tetradecanoyloxy)tetradecanoyl]amino-3-O-tetradecanoyl-4-O-sulfo-D-glucopyranose,
- (13) 2-deoxy-2-(3R-hydroxytetradecanoyl)amino-3-O-tetradecanoyl-4-O-sulfo-1,5-anhydro-D-glycitol????? or
- (14) methyl 2-deoxy-2-[3R-(tetradecanoyloxy)tetradecanoyl]amino-3-O-tetradecanoyl-4-O-sulfo- β -D-glucopyranoside.

8. A medicament for prevention and / or treatment described in claim 1, comprising as active ingredient, a glucopyranose derivative of formula (W)



- 84 -